Background: Loss of circadian rhythms and reduced concentrations of endogenous melatonin are common in critically ill patients. After exogenous administration, supra-physiological concentrations in serum are only ephemeral, which may explain the absence of significant therapeutic effect on sleep. The aim of this study is to describe the pharmacokinetics of enteral melatonin in critically ill patients administered in a novel regimen aiming to simulate endogenous release. Methods: Thirteen patients in the recovery phase of critical illness were randomised to receive enteral melatonin or placebo. In the melatonin group, a total of 6 mg was administered as solution through their feeding tube, commencing with a 3 mg loading dose at 9 pm and six subsequent 0.5 mg doses hourly. The placebo was administered using a similar regimen. Serial blood samples were taken and measured using a validated chromatographic method. The concentration-time data for serum melatonin
Introduction
Endogenous melatonin (N-acetyl-methoxytryptamine) is predominantly synthetised in the pinealocytes. Its synthesis is directly correlated with the intensity and length of darkness as well as by neuronal input from the suprachiasmatic nuclei. However, the oscillatory cycle of endogenous melatonin secretion is commonly disrupted by endogenous cortisol, absence of environmental input and idiosyncratic variability [1] . Moreover, critical illness in addition to the deprivation of natural zeitgebers associated to the intensive care environment further compromise this endogenous cycle [1] . Exogenous melatonin is used as a pharmacologic strategy to improve sleep in ICU [2] [3] [4] . Ongoing studies are trying to describe its clinical efficacy although its precise value is still unclear. A clinical trial compared placebo versus 3 mg oral melatonin twice daily in critically ill patients for improved sleep, the incidence of ICU-related delirium, length of stay and the reduction in other sedative doses required in these patients; with a reduction on analgesics and sedatives required as the main finding [5] . Another clinical trial compared the sedation-efficacy protocolised intravenous administration of propofol or midazolam with enteral therapies including melatonin [6] ; however, the efficacy of melatonin alone is not assessed.
Several studies have shown loss of circadian rhythm reducing endogenous melatonin [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] , with reduced total serum concentrations in critically ill patients [10] and supra-physiological plasma concentrations after exogenous administration [17] . To date, no study has demonstrated improved sleep or delirium incidence in critically ill patients by using any dose of melatonin. In the attempt to demonstrate pharmacological efficacy, some studies have used variable doses of melatonin [2] [3] [4] compromising that way, the comparison of their results. Meanwhile, the optimal dose of melatonin is still debated [1] .
Whilst the interest in melatonin has focussed on sleep and delirium, it is unclear whether it is associated with altered pharmacokinetics compared with other patient groups. Preserved oral bioavailability of melatonin with reduced plasma clearance (CL) in critically ill patients has been recently demonstrated [17] when using a single 3 mg dose supporting enteral administration despite gastrointestinal dysmotility being common in this group. However, melatonin's rapid onset, short half-life and firstpass metabolism may limit therapeutic effects. Normal endogenous melatonin concentration peaks between 2 am and 4 am at 60-70 pg/mL [18] . With the intention to reproduce these physiological concentrations, some investigators have evaluated the pharmacokinetics of melatonin when administered as an extended intravenous infusion in healthy subjects [8] . No studies have mimicked the pattern of endogenous release with exogenously melatonin administered in critically ill patients. The aim of the current study is to describe the pharmacokinetics (PK) of enteral melatonin in critically ill patients administered in a novel regimen aiming to simulate endogenous release.
Materials and methods
This study was approved by the Royal Brisbane and Women's Hospital, Human Research Ethics Committee (HREC/09.QRBW/262). Written informed consent was obtained from all subjects or critically ill adults' legal surrogates when the requirement for written informed consent was waived by the Ethics Committee.
Study population
A sample of critically ill patients in the recovery phase of their disease process were consecutively recruited to a double blind placebo controlled trial of enteral 6 mg of melatonin versus placebo via a nasogastric feeding tube as part of a larger clinical study on the effects on sleep and delirium in the critically ill. Inclusion criteria included: patients who were expected to have a minimal length of 5 days of respiratory weaning, and vasopressor free with preserved enteral absorption evidenced by nasogastric tube aspirates < 400 mL every 4 h, no ileus and having sedation weaned in preparation for extubation. For all patients bedside light intensity was reduced by turning off ceiling lights and offering eye pads. Noise reduction was managed by bedside nurse education and by offering the patient industrial ear plugs with a 36 dB reduction capacity. Light was measured at eye level using a lux-meter (LM-81LX light meter, CE) and noise was measured using an audiometer (IEC 651 Type II, CE). Relation between blood sampling and melatonin or placebo administration. For those patients receiving melatonin the intention was to reproduce the physiologic release of endogenous melatonin.
Timing of blood samples
Study drug dosing began with an enteral 3 mg loading dose at 9 pm followed by 0.5 mg enteral boluses hourly until 3 am, for a total of 6 mg ( Table 1 ). The study drug was administered as a solution by solubilising the contents of 3 mg capsules (Melatonin, Life Extension, USA) with water and flushing the required dose down the patient's nasogastric feeding tube. A similar regimen was followed for the placebo administration. This schedule intended to reproduce the normal physiological nocturnal release of melatonin. Drug administration compliance by bedside nurses was preserved and not different than any other prescribed medication to those patients. Blood samples were taken on the second night of study randomisation after having completed a first night of melatonin dosing.
Serum melatonin measurements
Sample plasma melatonin concentrations were determined using a high performance liquid chromatography assay method coupled with a tandem mass spectrometer (LC-MS/MS). Samples were prepared via protein precipitation and an acetonitrile solution, evaporated to dryness using nitrogen and reconstituted in mobile phase. Separation was achieved using a Waters Symmetry C8 column (150 × 3.9 mm, 5 μM particle size) using a gradient method.
Mobile phase A consisted of 18 MΩ H 2 O with 0.1% formic acid and mobile phase B consisted of 85% acetonitrile with 15% methanol. The gradient consisted of 70%:30% MP A:B, rising to 100% MP B over the first 5 min, holding at 100% MP B for 1 min before returning to 70%:30% MP A:B over 0.5 min to equilibrate for a further 1.5 min. The calibration range was extended and remained linear to a range of 31.25-10,000 ng/L with a correlation coefficient better than 0.998. Controls had accuracy better than 97% and CV of 4% or better. The standard curves prepared in plasma were compared with those prepared in water and there were no discernible ion suppression or matrix effects.
Pharmacokinetic analysis
The concentration-time data for serum melatonin concentrations were described using non-linear mixed-effects modeling (NONMEM version 7.3.0, ICON Development Solutions, Ellicott City, MD, USA) [19] . A Digital Fortran compiler was used and the runs were executed using Wings for NONMEM (http://wfn.sourceforge.net). Data were analysed using the first-order conditional estimation method with interaction. One and two compartment linear models with absorption were evaluated. Between-subject variability (BSV) was calculated using an exponential variability model. Residual unexplained variability was evaluated as additive, exponential or combined (additive plus exponential). Visual inspection of diagnostic scatter plots and the NONMEM objective function value (OFV) were used to evaluate goodness of fit. Statistical comparison of nested models was undertaken in the NONMEM program on the basis of a χ 2 -test of the difference in OFV. A decrease in the OFV of 3.84 units (p < 0.05) was considered statistically significant.
Bootstrap
A non-parametric bootstrap method (n = 1000) was used to study the uncertainty of all pharmacokinetic parameter estimates in the final base model. From the bootstrap empirical posterior distribution, we were able to obtain the 95% confidence interval (2.5%-97.5% percentile) for the parameters, as described previously [20] . 
Results
The 13 recruited patients' characteristics as well as melatonin concentrations distributed over the different timepoints are shown in Table 2 and Figure 1 , respectively. Blinded randomisation with administration of exogenous melatonin or placebo led to six of 13 subjects (subjects number : SN 3, SN 4, SN 6, SN 11, SN 12 and SN 13) showing quantifiable concentrations of melatonin in plasma. In these patients, the measured concentrations were significantly higher than endogenous melatonin concentrations in non-critically ill patients [21, 22] . Three of the other seven subjects showed extremely low concentrations of melatonin detected with four subjects having non-detectable concentrations of melatonin.
Pharmacokinetic model building and model evaluation
The time-course of melatonin concentrations was best described by a one-compartment model oral absorption model with exponential residual error and BSV on melatonin CL and the absorption rate constant (Ka).
Goodness of fit plots for the final model were evaluated and showed acceptable results in terms of visual or statistical biases (statistically significant systematic deviation away from the observed data) for predicted concentrations ( Figure 2) . Furthermore, the mean values for all parameters from the bootstrap analysis were similar to those in the final model (Table 3) . BSV, between subject variability; CL, clearance; CV, coefficient of variation; Ka, absorption rate constant; RUV, residual unexplained variability; V, volume of distribution. Observed melatonin concentrations in blood over the sampling interval for both groups with significant differences found along the observed time.
Discussion
The regimen of exogenous melatonin used in this study generally results in supra-physiological plasma concentrations in critically ill patients. This contrasts with the observations from the control group where melatonin concentrations were frequently undetectable. The concentrations observed in the placebo group were found to be 10-fold lower than the described endogenous peak concentrations of melatonin described in healthy populations [21, 22] this finding was expected considering the acute disease process in which these patients were involved. Low concentrations of endogenous melatonin in the critically ill patients relate to the effect of the disease process and reduction in environmental zeitgeber [10] [11] [12] [13] [14] [15] [16] . Supra-physiological concentrations of melatonin after exogenous administration has been described previously [9] and is consistent with our findings. Our baseline concentrations are comparable to those described by Mistraletti et al. [17] in critically ill patients with comparable plasma concentrations 45 min post single dose melatonin administration. Unlike Mistraletti's study, we attempted to design a regimen that mimics the endogenous pineal secretion in the non-critically ill. Our plasma concentrations are overall higher and more sustained than those described by Mistraletti, likely reflecting the additive effect of multiple doses. Two clear outliers were removed from the first PK sample (21 h) with final results at that sample time being as low as the placebo group. This is an expected finding as these patients would have their first PK sample prior to any melatonin administration; therefore only trace levels of melatonin in serum would be expected. Instead, on those two outliers, very high values of serum melatonin were found, likely as a result of a specimen collectiontime error, possibly with the PK sample being withdrawn after the drug was administered. With enteral melatonin showing a good bioavailability, it is likely that these two outliers had already detectable concentrations in serum minutes after a first dose. Supra-physiological levels of serum melatonin were also found in the morning hours (9 am) without affecting patient's alertness, with an additive effect from multiple dosing as the main identifiable reason for this finding. Serum levels of melatonin in the placebo group were distributed more evenly showing significantly lower serum levels than in the melatonin group.
An accepted limitation on the efficacy of melatonin specifically in intensive care has been its short onset as well as its spurious effect. Previous studies have demonstrated very low concentrations of melatonin amongst critically ill patients [2, 23] , with no significant impact on sleep after the exogenous administration of one single dose of melatonin [2] . However, there have been no previous studies quantifying the clinical or analytical effect of multiple doses of melatonin in critically ill patients. Such a regimen could, in our opinion, bypass the transient effect of single dosing of melatonin. Whilst the focus of this study is the pharmacokinetic analysis of a new administration regimen of melatonin and not the assessment of its clinical efficacy, the authors believe that a regimen of serial administrations may contribute to the maintenance of high serum melatonin concentrations through the night, perhaps positively influencing nocturnal sleep in these patients.
Controversy remains as to whether "high and sustained" concentrations of plasma melatonin can be regularly achieved in the critically ill and whether such concentrations are needed for clinical efficacy. Our study demonstrates for first time that following a loading dose of 3 mg and hourly dosing of 0.5 mg, patients maintain supraphysiological plasma concentrations of melatonin for 12 h overnight. In addition, our study supports the findings of Mistraletti et al., confirming that despite a first-pass effect or pharmacological interactions on the enteral absorption of melatonin in critically ill patients, the enteral administration of melatonin is a feasible option with excellent oral bioavailability. Further investigations continue into the sleep effects of repeated melatonin administration in critically ill patients.
Conclusions
This study demonstrates that exogenous administration of melatonin with a loading dose of 3 mg, followed by an hourly dose of 0.5 mg, results in supra-physiological and sustained concentrations of serum melatonin during 12 h overnight. These findings confirm good oral bioavailability of melatonin and lead to the question of its clinical impact on sleeping amongst critically ill patients. Further clinical studies assessing the efficacy at these levels of serum melatonin are warranted.
